<DOC>
	<DOCNO>NCT01779830</DOCNO>
	<brief_summary>The aim study learn different dos LY2624803 affect sleep healthy people . The study four treatment period . Participants receive single dose LY2624803 , another sleeping pill , placebo treatment period . The study last approximately 1 month participant .</brief_summary>
	<brief_title>A Study LY2624803 Participants With Transient Insomnia</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Zolpidem</mesh_term>
	<criteria>Overtly healthy male female Women childbearing potential , test negative pregnancy time enrollment base urine pregnancy test agree use reliable method birth control study one month follow last dose study drug Between Body Mass Index ( BMI ) 19 30 kilogram per meter square ( kg/m^2 ) , inclusive Normal bedtime hour , routine time spend bed 6.5 hour 9 hour night Participants whose daily caffeine intake permit maintenance normal bed time hour Non response placebo define Wake After Sleep Onset ( WASO ) great equal 45 minute , 5hour phaseadvanced polysomnography ( PSG ) screen night bedtime singleblind placebo administration Males must agree use effective barrier contraception course trial 3 month later Participants 65 year age , stable dose one medication lower cholesterol , triglycerides and/or one medication lower blood pressure and/or substitutive hormonal therapy post menopausal woman allow provided treatment central effect Clinical laboratory test result within normal reference range judge clinically significant Normal sit blood pressure pulse rate determine Venous access sufficient allow blood sampling Are reliable willing make available duration study Have give write informed consent approve Lilly ethical review board govern site Shift worker ( shift work within 7 day PSG night ) person cross ( cross ) one time zone aircraft within 3 day prior entry Rhinoconjunctivitis , urticaria chronic pain severe enough interfere sleep Nocturia would interfere sleep assessment Participants allergic conjunctivitis urticaria Regular napping ( great ( â‰¥ ) 2 daytime naps/week history ) Symptoms consistent sleep disorder history Sleep disorder detect screen night Evidence significant active neuropsychiatric disease particular evidence significant medical psychiatric illness within past 12 month could contribute insomnia Irregular alter sleep/wake schedule Known history faint low blood pressure . History cranial trauma loss consciousness discuss prior include participant Within 3 month initial dose study drug , receive treatment drug receive regulatory approval indication Participants postural hypotension screen Participants history postural hypotension , loss consciousness , explain unexplained syncope seizure episodes family history seizure . History single febrile convulsion acceptable Known allergy LY2624803 , Zolpidem relate compound Persons previously complete withdrawn study study investigate LY2624803 An abnormality 12lead electrocardiogram ( ECG ) increase risk associate participate study History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurocardiogenic neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Any condition opinion investigator would preclude participation study Regular use know drug abuse and/or positive finding urinary drug screen Evidence Human Immunodeficiency Virus ( HIV ) and/or positive human HIV antibody Evidence hepatitis C and/or positive hepatitis C antibody Evidence hepatitis B and/or positive hepatitis B surface antigen Women positive pregnancy test Women lactate Use prescription , counter herbal medication safely discontinue within 28 day prior enrollment Blood donation 500 milliliter ( mL ) within last month History smoking within previous 6 month screen Participants average weekly alcohol intake exceed 28 unit per week ( male ) 21 unit per week ( female ) , participant unwilling stop alcohol consumption duration study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>